Identification of a domain which affects kinetics and antagonistic potency of clozapine at 5-HT3 receptors.
The widely used atypical antipsychotic clozapine is a potent competitive antagonist at 5-HT(3) receptors which may contribute to its unique psychopharmacological profile. Clozapine binds to 5-HT(3) receptors of various species. However, the structural requirements of the respective binding site for clozapine remain to be determined. Differences in the primary sequences within the 5-HT(3A) receptor gene in schizophrenic patients may result in an alteration of the antipsychotic potency and/or the side effect profile of clozapine. To determine these structural requirements we constructed chimeras with different 5-HT(3A) receptor sequences of murine and human origin and expressed these mutants in human embryonic kidney (HEK) 293 cells. Clozapine antagonises recombinant mouse 5-HT(3A) receptors with higher potency compared to recombinant human 5-HT(3A) receptors. 5-HT activation curves and clozapine inhibition curves yielded the parameters EC(50) and IC(50) for all receptors tested in the range of 0.6 - 2.7 microM and 1.5 - 83.3 nM, respectively. The use of the Cheng-Prusoff equation to calculate the dissociation constant K(b) values for clozapine revealed that an extracellular sequence (length 86 aa) close to the transmembrane domain M1 strongly determines the binding affinity of clozapine. K(b) values of clozapine were significantly lower (0.3-1.1 nM) for receptors containing the murine sequence and higher when compared with receptors containing the respective human sequence (5.8-13.4 nM). Thus, individual differences in the primary sequence of 5-HT(3) receptors may be crucial for the antipsychotic potency and/or the side effect profile of clozapine.
Rammes
Gerhard
G
Max Planck Institute of Psychiatry, Munich, Germany. rammes@mpipsykl.mpg.de
Hosp
Christine
C
Eisensamer
Brigitte
B
Tanasic
Sascha
S
Nothdurfter
Caroline
C
Zieglgänsberger
Walter
W
Rupprecht
Rainer
R
D000595:Amino Acid Sequence; D000818:Animals; D014150:Antipsychotic Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D002460:Cell Line; D003024:Clozapine / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D008969:Molecular Sequence Data; D018408:Patch-Clamp Techniques; D044406:Receptors, Serotonin, 5-HT3 / Q000737:chemistry; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors; D017386:Sequence Homology, Amino Acid; D058831:Serotonin 5-HT3 Receptor Antagonists
D014150:Antipsychotic Agents; D044406:Receptors, Serotonin, 5-HT3; D011994:Recombinant Proteins; D058831:Serotonin 5-HT3 Receptor Antagonists; D003024:Clozapine
Neurobiol Aging. 1997 Jan-Feb;18(1):21-8
8983029
Pharmacogenet Genomics. 2008 Aug;18(8):721-7
18622264
J Physiol. 1992 Mar;448:237-56
1375636
Neurosci Biobehav Rev. 1999 Dec;23(8):1111-25
10643820
Trends Pharmacol Sci. 1998 Jun;19(6):212-5
9666711
J Biol Chem. 2006 Aug 4;281(31):21781-21788
16754678
BMC Neurosci. 2006 Mar 29;7:27
16571125
Expert Opin Ther Targets. 2007 Apr;11(4):527-40
17373882
Trends Neurosci. 2000 Dec;23(12):605-10
11137150
Biophys J. 2003 Mar;84(3):1720-33
12609874
J Neurosci. 1997 Nov 1;17(21):8353-62
9334409
J Neurosci. 1998 Aug 15;18(16):6528-38
9698340
Trends Pharmacol Sci. 2005 Nov;26(11):587-94
16194573
Biochem Biophys Res Commun. 1996 Aug 23;225(3):957-60
8780717
Mol Pharmacol. 1998 Feb;53(2):202-12
9463477
Mol Cell Neurosci. 2002 Sep;21(1):38-50
12359150
Alcohol. 2006 Nov;40(3):167-76
17418696
Neuron. 1992 Jan;8(1):199-203
1346089
Schizophr Res. 2002 Nov 1;58(1):93-7
12363396
Int Rev Psychiatry. 2007 Aug;19(4):337-45
17671867
Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11456-61
9736758
Psychopharmacology (Berl). 1996 May;125(2):146-61
8783389
Schizophr Res. 2009 Feb;107(2-3):206-12
18789844
Science. 1991 Oct 18;254(5030):432-7
1718042
Pharmacogenetics. 2001 Feb;11(1):21-7
11207027
J Mol Neurosci. 2006;30(3):273-81
17401153
Mol Neurobiol. 2007 Apr;35(2):160-74
17917105
Neuropsychopharmacology. 1995 Nov;13(3):177-213
8602893
J Physiol. 2000 Dec 1;529 Pt 2:373-83
11101647
Behav Brain Res. 1996;73(1-2):1-5
8788468
Neuropharmacology. 1999 Aug;38(8):1083-152
10462127
Br J Pharmacol. 1996 Aug;118(7):1836-40
8842451
Eur J Pharmacol. 1990 Jul 17;182(3):465-72
1977590
Neuroscientist. 2003 Oct;9(5):404-16
14580124
J Physiol. 1994 Dec 1;481 ( Pt 2):311-23
7537814
Br J Pharmacol. 2008 Apr;153(7):1474-84
18204482
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
4202581
Eur J Pharmacol. 1988 Oct 18;155(3):349-50
3234491
Nature. 2003 Jul 17;424(6946):321-4
12867984
Fortschr Neurol Psychiatr. 2005 Nov;73 Suppl 1:S32-7
16270242
Neuron. 1988 Sep;1(7):615-21
3272181
Mol Pharmacol. 1995 Sep;48(3):407-16
7565620
Neurosci Lett. 1995 Sep 1;197(1):57-60
8545056
Mol Endocrinol. 1998 Sep;12(9):1441-51
9731711
Trends Pharmacol Sci. 1992 Mar;13(3):116-21
1349447
Nature. 1993 Dec 2;366(6454):479-83
8247158
Mol Pharmacol. 1995 Dec;48(6):1054-62
8848005
Br J Pharmacol. 1996 Mar;117(5):839-46
8851499
Mol Psychiatry. 2004 Sep;9(9):846-58, 818
15024394
Ann Clin Psychiatry. 2003 Mar;15(1):33-48
12839431
Nature. 1999 Jan 28;397(6717):359-63
9950429